This portal is your one-stop-shop for all your needs and questions concerning BMS products in Switzerland! These are some examples of the things you can find:
Ready to explore? Please use your existing DocCheck Login to access one of our therapeutic area portals or to access the comprehensive BMS Medicines or News & Events overview
Februar 2024 – OPDUALAG® (nivolumab/relatlimab) is now reimbursed for the first-line treatment of adults with metastatic melanoma with PD-L1 < 1% expression.
November 2023 – Q4W 480 mg dosing with OPDIVO® (nivolumab) is approved in all melanoma indications.
Q4W dosing is approved for all Nivolumab monotherapy as well as monotherapy maintenance after Nivolumab + Ipilimumab combination treatment in melanoma.
October 2023 – OPDIVO® (nivolumab) as monotherapy is indicated for the adjuvant treatment of adults with completely resected Stage IIB or IIC melanoma.
September 2023 – Swissmedic approved BREYANZI® (lisocabtagene maraleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL) or primary mediastinal large B-cell lymphoma (PMBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.
BREYANZI®
▼ This drug is subject to additional monitoring. For further information, please refer to the information for healthcare professionals on swissmedicinfo.ch.
More information
July 2023 – OPDIVO® (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumour size ≥ 4 cm or positive lymph node involvement) non-small cell lung cancer (NSCLC) with PD-L1 tumour expression ≥ 1 % in adults
December 2022 – OPDUALAG® (nivolumab/relatlimab) for the first-line treatment of adults with unresectable or metastatic melanoma with PD-L1 expression < 1%.
03/2024 7356-CH-2400012